HTFL · Heartflow, Inc.

Current Thesis

Heartflow’s post-earnings re-rating rests on faster diagnostic revenue growth; a weekly close above the $50.43 reference high would confirm continuation, while a weekly close below $42 would invalidate it. The 2026-09-11 adjusted close was $49.88, with a three-month price increase of 50.1% and a 14-day relative strength index (RSI) of 50.4, according to the adjusted daily series.

The principal change since the September 3 assessment is analyst coverage: UBS initiated at Neutral with a $55 price target on 2026-09-09. The earlier claim that the shares exceeded every published target no longer holds, although UBS’s rating does not establish a bullish consensus. Benzinga analyst actions

The narrative is maturing — this is an inference from the 2026-08-13 guidance increase, the 2026-08-28 FUSION presentation and the subsequent September coverage, rather than evidence of another earnings acceleration. The September 9 conference has elapsed, and the company’s events page lists no upcoming event as checked on 2026-09-13. That calendar does not establish what management said during the conference. Heartflow events

Bullish and bearish views on Heartflow, Inc.

The model's bull view on Heartflow, Inc. (HTFL), in brief: Revenue supports the operating story. Heartflow reported second-quarter 2026 revenue of $64.1 million, up 48% year over year, on 2026-08-13. It raised full-year revenue guidance to $246–250 million from $228–232 million. Company results Plaque provides a separate test.… The bear view: Profitability remains an unfinished transition. Both cases follow in full.

Bull Case

• Revenue supports the operating story. Heartflow reported second-quarter 2026 revenue of $64.1 million, up 48% year over year, on 2026-08-13. It raised full-year revenue guidance to $246–250 million from $228–232 million. Company results
• Plaque provides a separate test. Management’s 2026-08-13 earnings call reported second-quarter Plaque revenue of $7.8 million and a full-year Plaque outlook of $29–31 million. Retention of that outlook at the next results would support the commercial expansion thesis; a reduction would contradict it.
• Clinical evidence supports diagnostic utility. The FUSION results presented on 2026-08-28 covered 528 patients at 12 Dutch hospitals. Unnecessary invasive coronary angiography occurred in 22% of patients receiving computed tomography-derived fractional flow reserve analysis (FFRCT), versus 39% receiving coronary computed tomography angiography alone; revascularization was 20% in both groups, according to Heartflow’s trial announcement. These are clinical outcomes, not measured revenue conversion.
• The analyst ceiling has changed. UBS’s 2026-09-09 target of $55 exceeds the $45 upper target cited in the August 14 analyst round. This removes a specific objection in the previous assessment without demonstrating that demand has broadened. Benzinga analyst actions

Bear Case

• Profitability remains an unfinished transition. Heartflow’s 2026-08-13 results reported second-quarter adjusted earnings before interest, taxes, depreciation and amortization of negative $6.7 million. Gross margin was 83.0%, but that margin had not produced positive adjusted operating earnings. Company results
• Attention does not measure participation. Benzinga’s 2026-09-08 headline reported attention from Investor’s Business Daily SwingTrader, followed by UBS’s initiation on 2026-09-09. This coverage sample is too small to establish retail crowding, sustained inflows or a widening shareholder base.
• Officer dispositions remain relevant context. StockTitan filing summaries cited officer dispositions reported on 2026-08-20, 2026-08-21 and 2026-08-25 under prearranged trading plans. Those historical filings document supply; they do not establish informed pessimism or continuing September sales.

Setup & Price Structure

The 2026-09-11 adjusted close of $49.88 was 1.1% below the supplied $50.43 reference high. RSI was 50.4, compared with the 88.0 reading recorded on 2026-09-02. The earlier overbought characterization therefore no longer describes the supplied indicator, although the September 11 close still had not exceeded the reference high.

The structural continuation case is a weekly close above $50.43 before a weekly close below $42. The lower threshold remains tied to the $42.08 gap-day close recorded on 2026-08-14. Moving-average values and a volume series are absent, so neither support from a rising average nor accumulation can be established.

Catalyst Calendar (next 30 days)

• ~2026-11-12, est.: Third-quarter results. This remains an unconfirmed estimate, not a company announcement. The report is the next identified operating test of the $246–250 million full-year revenue guidance and $29–31 million Plaque outlook stated on 2026-08-13; a reduction in either would contradict the commercial thesis.

Elapsed catalysts

• 2026-09-13 calendar check: Heartflow’s official events page lists the 2026-09-09 Wells Fargo conference among past events and no upcoming company event. No company-confirmed catalyst date is available for the next 30 days. Heartflow events (passed 7d ago)

What Would Change Our Mind

Loss of the post-earnings shelf would break the structural thesis: a weekly close below $42 would place the market beneath the 2026-08-14 gap-day close of $42.08. A reduction in the revenue or Plaque outlook issued on 2026-08-13 would independently undermine the operating argument, even if that price threshold remained intact.

A weekly close above the $50.43 reference high reported in the 2026-09-11 price series would satisfy the near-term continuation test. Retaining both revenue outlooks at the next quarterly report would provide separate operating confirmation; the $55 UBS target dated 2026-09-09 is an analyst forecast, not that confirmation.

Correlation Notes

The Medtech & diagnostics coverage cluster moved from accelerating on 2026-08-30 to maturing on 2026-09-06 and saturated on 2026-09-13. Those editorial classifications describe the group’s narrative progression; they do not establish that Heartflow itself is saturated.

The September 13 cluster includes INSP, ATRC, PRPO, BFLY and TXG, but paired return observations are absent. The evidence supports thematic association only, with no measured correlation or demonstrated diversification relationship. Heartflow’s dated guidance and published price conditions remain the company-specific tests.